Revised national tuberculosis control programme in India has limited cohort-wise information about what happens to patients diagnosed with multidrug resistant TB (MDR-TB). We determined the pre-treatment loss to follow-up (non-initiation of treatment by programme within 6 months of diagnosis) and time from diagnosis to treatment initiation in Bhopal district, central India (2014). Pre-treatment loss to follow-up was 13% (0.95 CI: 7%, 23%), not significantly different from the national estimates (18%) and median time to initiate treatment was seven days, lower than that reported elsewhere in the country. Bhopal was performing well with reference to time to treatment initiation in programmatic settings.
Introduction
India has highest burden of multidrug-resistant/rifampicin-resistant tuberculosis [3] . Here, we report the pre-treatment loss to follow-up (between confirmed MDR-TB and treatment initiation) and time from diagnosis to treatment initiation.
Methods
Bhopal district is situated in Madhya Pradesh, the second largest state in India. It has a population of 2.53 million and is predominantly urban. Bhopal district contains Bhopal city which is the capital of Madhya Pradesh [4] .
In Bhopal district, during 2014 the diagnostic facility for MDR-TB was the national reference laboratory (NRL), located in a tertiary public health care facility.
It is certified by RNTCP for proficiency in phenotypic (solid/liquid culture and drug susceptibility testing [C-DST]) and molecular diagnostic techniques (line probe assay-LPA and cartridge-based nucleic acid amplification test-CbNAAT).
In quarter 1 (January-March) 2014, if specimen was smear positive, then LPA was used upfront. Among smear negative specimens, culture was done followed by LPA, if culture turned out to be positive. Quarter 2 (April-June) 2014 onwards, LPA was used for smear positive and CbNAAT was used for smear negative specimens.
After diagnosis, treatment initiation was ensured at DR-TB center by the district health staff. Treatment was according to RNTCP programmatic management of DR-TB (PMDT) guidelines which were in line with then WHO recommendations [5] . Patients with RR-TB were also treated with the standard MDR-TB regimen. Therefore, MDR-TB included RR-TB as well.
This was a retrospective cohort study involving record review of all patients belonging to Bhopal district and diagnosed with MDR-TB under RNTCP in 2014. Each study participant was tracked from NRL C-DST register to PMDT treatment register at DR-TB center. 
Results
There were 74 patients diagnosed with MDR-TB: mean (SD) age in years was 32
(12) and 46 (62%) were males. History of "previously treated TB" was seen in 54 (73%) cases. The diagnostic test used was LPA for 62 (84%) and CbNAAT for 12 (16%).
Ten out of 74 patients (13%, 0.95 CI (7%, 23%)) underwent pre-treatment loss to follow-up (Figure 1 ). Among 64 patients initiated on treatment and dates being available (n = 59), median time (IQR) from diagnosis to treatment initiation was 7 (4, 11) days and 80% (47/59) were initiated on treatment within 14 days (Table 1) .
There was no significant association of demographic and clinical factors with pre-treatment loss to follow-up/time to initiate treatment (data not shown). 
Discussion
Pre-treatment loss to follow-up among patients with MDR-TB in programmatic setting was not significantly different from the national estimate of 18% [1].
Median time to initiate treatment was shorter than that reported elsewhere in the country: 19 days in Delhi, 10 days in Puducherry and 20 -23 days in Chennai [6] [7] [8] . There is further scope for improvement in reduction of pre-treatmentloss to follow-up. The programme is concerned about this and understanding why some patients are not willing to start treatment after diagnosis needs further systematic qualitative inquiry.
Previously, we found 60% pre-diagnosis loss to follow-up among patients with presumptive MDR-TB in 2014 in Bhopal, largely contributed by failure to refer patients for DST [3] . Considering the minimal pre-diagnosis loss to follow-up at the level of NRL [3] and the low pre-treatment loss to follow-up identified in this study, we can infer that performance of the diagnostic and treatment pathway was satisfactory once the sample reached the NRL.
Data collected was double entered and validated minimizing data entry errors.
Study was conducted in operational settings reflecting the ground realities. The sample size was not being sufficient for risk factor analysis was the major limitation.
PMDT in Bhopal was performing well with reference to time to treatment initiation among patients with MDR-TB. There is a need to increase counselling and patient tracking mechanisms if we are to minimize pre-treatment loss to follow-up, time to treatment initiation and ensure survival for all patients diagnosed with MDR-TB.
